Clinical, virological, immunological and pathological evaluation of four porcine circovirus type 2 vaccines

Veterinary Journal

Volumn 200, Issue 1, 2014, Pages 65-70

  Seo, Hwi Won ^a   Han, Kiwon ^a   Park, Changhoon ^a   Chae, Chanhee ^a  

^a Seoul National University   (South Korea)

Author keywords

PCV associated disease; Porcine circovirus (PCV) type 2; Post weaning multisystemic wasting syndrome; Vaccine

Indexed keywords

CIRCOFLEX; CIRCOVAC; CIRCOVIRUS 2 VACCINE; DNA; FOSTERA PCV; GAMMA INTERFERON; PORCILIS PCV; SUVAXYN; UNCLASSIFIED DRUG; VIRUS VACCINE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SMEAR; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CIRCOVIRIDAE INFECTION; CIRCOVIRUS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNOLOGY; NONHUMAN; NOSE SMEAR; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; TREATMENT DURATION; VIROLOGY; WEIGHT GAIN; ANIMAL; BLOOD; CELLULAR IMMUNITY; CIRCOVIRIDAE INFECTIONS; HUMORAL IMMUNITY; PORCINE POSTWEANING MULTISYSTEMIC WASTING SYNDROME; SOUTH KOREA; SWINE; VACCINATION; VETERINARY; VIREMIA;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CIRCOVIRIDAE INFECTIONS; CIRCOVIRUS; DNA, VIRAL; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; PORCINE POSTWEANING MULTISYSTEMIC WASTING SYNDROME; REPUBLIC OF KOREA; SWINE; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES; VIREMIA;

EID: 84898779564     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2014.02.002     Document Type: Article

References (31)

1. Allan G.M., Mackie D.P., McNair J., Adair B.M., McNulty M.S. Production, preliminary characterisation and applications of monoclonal antibodies to porcine circovirus. Veterinary Immunology and Immunopathology 1994, 43:357-371.
2. Brunborg I.M., Moldal T., Jonassen C.M. Quantitation of porcine circovirus type 2 isolated from serum/plasma and tissue samples of healthy pigs and pigs with postweaning multisystemic wasting syndrome using a TaqMan-based real-time PCR. Journal of Virological Methods 2004, 122:171-178.
3. Chae C. Postweaning multisystemic wasting syndrome: a review of aetiology, diagnosis and pathology. The Veterinary Journal 2004, 168:41-49.
4. Chae C. A review of porcine circovirus 2-associated syndromes and diseases. The Veterinary Journal 2005, 169:326-336.
5. Chae C. Commercial porcine circovirus type 2 vaccines: Efficacy and clinical application. The Veterinary Journal 2012, 194:151-157.
6. Diaz I., Mateu E. Use of ELISPOT and ELISA to evaluate IFN-γ, IL-10 and IL-4 responses in conventional pigs. Veterinary Immunology and Immunopathology 2005, 106:107-112.
7. Fenaux M., Halbur P.G., Haqshenas G., Royer P., Thomas P., Nawagitgul P., Gill M., Toth T.E., Meng X.J. Cloned genomic DNA of type 2 porcine circovirus is infectious when injected directly into the liver and lymph nodes of pigs: Characterization of clinical disease, virus distribution, and pathologic lesions. Journal of Virology 2002, 76:541-551.
8. Fort M., Olvera A., Sibila M., Segalés J., Mateu E. Detection of neutralizing antibodies in postweaning multisystemic wasting syndrome (PMWS)-affected and non-PMWS-affected pigs. Veterinary Microbiology 2007, 125:244-255.
9. Fort M., Sibila M., Allepuz A., Mateu E., Roerink F., Segalés J. Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins. Vaccine 2008, 26:1063-1071.
10. Fort M., Fernandes L.T., Nofrarias M., Diaz I., Sibila M., Pujols J., Mateu E., Segalés J. Development of cell-mediated immunity to porcine circovirus type 2 (PCV2) in caesarean-derived, colostrum-deprived piglets. Veterinary Immunology Immunopathology 2009, 129:101-107.
11. Fort M., Sibila M., Perez-Martin E., Nofrarias M., Mateu E., Segalés J. One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model. Vaccine 2009, 27:4031-4037.
12. Fraile L., Grau-Roma L., Sarasola P., Sinovas N., Nofrarias M., Lopez-Jimenez R., Lopez-Soria S., Sibila M., Segalés J. Inactivated PCV2 one shot vaccine applied in 3-week-old piglets: Improvement of production parameters and interaction with maternally derived immunity. Vaccine 2012, 30:1986-1992.
13. Gagnon C.A., del Castillo J.R., Music N., Fontaine G., Harel J., Tremblay D. Development and use of a multiplex real-time quantitative polymerase chain reaction assay for detection and differentiation of Porcine circovirus-2 genotypes 2a and 2b in an epidemiological survey. Journal of Veterinary Diagnostic Investigation 2008, 20:545-558.
14. Kim D., Ha Y., Lee Y.H., Chae S., Lee K., Han K., Kim J., Lee J.-H., Kim S.-H., Hwang K.-K., Chae C. Comparative study of in situ hybridization and immunohistochemistry for the detection of porcine circovirus 2 in formalin-fixed, paraffin-embedded tissues. Journal of Veterinary Medical Science 2009, 71:1001-1004.
15. Kixmoller M., Ritzmann M., Eddicks M., Saalmuller A., Elbers K., Fachinger V. Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2. Vaccine 2008, 26:3443-3451.
16. Liu Q., Wang L., Willson P., Babiuk A. Quantitative, competitive PCR analysis of porcine circovirus DNA in serum from pigs with postweaning multisystemic wasting syndrome. Journal of Clinical Microbiology 2000, 38:3474-3477.
17. Martelli P., Ferrari L., Morganti M., Angelis D.E., Bonilauri P., Guazzetti S., Caleffi A., Borghetti P. One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions. Veterinary Microbiology 2011, 149:339-351.
18. Meerts P., Van-Gucht S., Cox E., Vandebosch A., Nauwynck H.J. Correlation between type of adaptive immune response against porcine circovirus type 2 and level of virus replication. Viral Immunology 2005, 18:333-341.
19. Meerts P., Misinzo G., Lefebvre D., Nielsen J., Botner A., Kristensen C.S., Nauwynck H.J. Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease. BMC Veterinary Research 2006, 2:6.
20. Olvera A., Sibila M., Calsamiglia M., Segalés J., Domingo M. Comparison of porcine circovirus type 2 load in serum quantified by a real time PCR in postweaning multisystemic wasting syndrome and porcine dermatitis and nephropathy syndrome naturally affected pigs. Journal of Virological Methods 2004, 117:75-80.
21. O'Neill K.C., Shen H.G., Lin K., Hemann M., Beach N.M., Meng X.J., Halbur P.G., Opriessnig T. Studies on porcine circovirus type 2 vaccination of 5-day-old piglets. Clinical and Vaccine Immunology 2011, 18:1865-1871.
22. Opriessnig T., Patterson A.R., Madson D.M., Pal N., Halbur P.G. Comparison of efficacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV-PCV2-SIV clinical infection model 2-3-months post vaccination. Vaccine 2009, 27:1002-1007.
23. Pogranichnyy R.M., Yoon K.J., Harms P.A., Swenson S.L., Zimmerman J.J., Sorden S.D. Characterization of immune response of young pigs to porcine circovirus type 2 infection. Viral Immunology 2000, 13:143-153.
24. Saalmüller A., Bryant J. Characteristics of porcine T lymphocytes and T-cell lines. Veterinary Immunology and Immunopathology 1994, 43:45-52.
25. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-γ: An overview of signals, mechanisms and functions. Journal of Leukocyte Biology 2004, 75:163-189.
26. Segalés J., Alonso F., Rosell C., Pastor J., Chianini F., Campos E., Lopez-Fuertes L., Quintana J., Rodriguez-Arrioja G., Calsamiglia M., et al. Changes in peripheral blood leukocytes populations in pigs with natural postweaning multisystemic wasting syndrome (PMWS). Veterinary Immunology and Immunopathology 2001, 81:37-44.
27. Segalés J., Calsamiglia M., Olvera A., Sibila M., Badiella L., Domingo M. Quantification of porcine circovirus type 2 (PCV2) DNA in serum and tonsillar, nasal, tracheo-bronchial, urinary and faecal swabs of pigs with and without postweaning multisystemic wasting syndrome (PMWS). Veterinary Microbiology 2005, 11:223-229.
28. Segalés J., Urniza A., Alegre A., Bru T., Crisci E., Nofrarias M., Lopez-Soria S., Balasch M., Sibila M., Xu Z., et al. A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms. Vaccine 2009, 27:7313-7321.
29. Seo H.W., Han K., Oh Y., Park C., Chae C. Efficacy of a reformulated inactivated chimeric PCV1-2 vaccine based on clinical, virological, pathological and immunological examination under field conditions. Vaccine 2012, 30:6671-6677.
30. Shen H.G., Beach N.M., Huang Y.W., Halbur P.G., Meng X.J., Opriessnig T. Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV). Vaccine 2010, 28:5960-5966.
31. Sosa G.A., Quiroga M.F., Roux M.E. Flow cytometric analysis of T-lymphocytes from nasopharynx-associated lymphoid tissue (NALT) in a model of secondary immunodeficiency in Wistar rats. Immunobiology 2009, 214:384-391.